Zhao Qiyi, Zhang Geng-Lin, Zhu Xiang, Su Di, Huang Zhan-Lian, Hu Zhao-Xia, Peng Liang
Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Guangdong Key Laboratory of Liver Disease Research, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
J Gastroenterol Hepatol. 2017 Aug;32(8):1520-1524. doi: 10.1111/jgh.13678.
The herpes virus entry mediator (HVEM) network has become new directions in targeting novel checkpoint inhibitors for cancer therapy. However, the changes of membrane-bound HVEM (mHVEM) and soluble HVEM (sHVEM) in hepatocellular carcinoma (HCC) are not fully understood. This study aims to study the changes of mHVEM and sHVEM in HCC patients.
Serum samples were collected from 65 HCC patients, from which sHVEM levels were examined by enzyme-linked immunosorbent assay. Expressions of mHVEM on peripheral lymphocytes from 20 HCC patients were determined using flow cytometry, and associations between mHVEM on T and B cells were analyzed.
The levels of mHVEM were downregulated on peripheral lymphocytes in HCC patients, with a strong positive correlation between mHVEM expression on T and B cells. In contrast, the levels of soluble HVEM were upregulated in the serum of HCC patients. Furthermore, we found that the increase in sHVEM level was correlated with advanced stages HCC.
Our data demonstrated paradoxical changes of membrane and soluble HVEM in the peripheral blood of HCC patients for the first time. These data supported the notion that roles of HVEM are likely to be immunosuppressive rather than activating tumor immunity. Future studies are warranted to further explore the translational values of mHVEM and sHVEM in peripheral blood as diagnostic markers and therapeutic targets.
疱疹病毒进入介质(HVEM)网络已成为癌症治疗中新型检查点抑制剂的新靶点。然而,肝细胞癌(HCC)中膜结合型HVEM(mHVEM)和可溶性HVEM(sHVEM)的变化尚未完全明确。本研究旨在探讨HCC患者中mHVEM和sHVEM的变化。
收集65例HCC患者的血清样本,采用酶联免疫吸附测定法检测sHVEM水平。使用流式细胞术测定20例HCC患者外周淋巴细胞上mHVEM的表达,并分析T细胞和B细胞上mHVEM之间的相关性。
HCC患者外周淋巴细胞上mHVEM水平下调,T细胞和B细胞上mHVEM表达之间呈强正相关。相反,HCC患者血清中可溶性HVEM水平上调。此外,我们发现sHVEM水平的升高与晚期HCC相关。
我们的数据首次证明了HCC患者外周血中膜结合型和可溶性HVEM的矛盾变化。这些数据支持了HVEM的作用可能是免疫抑制而非激活肿瘤免疫的观点。未来的研究有必要进一步探索外周血中mHVEM和sHVEM作为诊断标志物和治疗靶点的转化价值。